Laserfiche Joins the Boomi Technology Partner Program, Supporting the Automated, Connected Enterprise
22.2.2023 17:00:00 EET | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced a partnership with Boomi, a leading provider of integration platform as a service known for its speed, ease-of-use, and low total cost of ownership. Through this partnership, organizations can simplify integrations between Laserfiche's robust content services platform and on-premises and cloud applications such as Salesforce, Workday, and Smartsheet using Boomi’s connectors to over 1,500 applications.
“Today’s connected enterprise is built on a robust technology infrastructure, which requires a centralized system to collect and monitor process data, paired with a simplified integration strategy,” said David Everson, Laserfiche’s senior director of strategic solutions. “Laserfiche is excited to bring a proven system for data centralization and process automation to the Boomi ecosystem, enabling more speed, greater agility and stronger security in our customers’ integrations.”
Laserfiche supports organizations in building end-to-end automated solutions that boost productivity, scale with growth and deliver digital-first customer experiences. Laserfiche customers can now take advantage of the enterprise content management (ECM) platform’s Boomi-powered connectors to mission-critical line-of-business applications accelerate integration deployment, more easily manage integration lifecycles and access organization-wide data analytics. The Laserfiche and Boomi partnership is enabling customers to configure and expedite solutions such as:
- Streamlined recruiting and new employee onboarding to move candidates through the hiring process quickly
- Sending/retrieving data to/from popular storage and databases for more flexible data queries and reporting
- Streamlined invoice processing to gain real-time visibility into accounts payable
- Syncing client updates to provide the business with a more holistic view of the client
- Simplified authentication for secure connections to applications
According to The Forrester Wave™: Enterprise iPaaS, Q4 2021, “As more organizations embrace cloud-native, applications and data are more distributed than ever before. Delivering those user experiences and digital business capabilities requires an integration platform that stitches together the ever-growing number of distributed apps and data. Furthermore, the pandemic and quarantines accelerated the need for business process automation and has squeezed IT beyond what it can deliver. In response, organizations are embracing citizen iPaaS as a tool in their business process automation strategy.”
The Boomi Technology Partner Program includes enterprise software companies across applications such as CRM, ERP, HRIS and business intelligence, as well as across industries including government, education, financial services, healthcare and manufacturing. Boomi provides organizations with greater scalability and greater control over data orchestration between application transactions, allowing connectivity to scale as organizations adopt a wider range of solutions.
“We are excited to have Laserfiche as part of our Technology Partnership Program,” said Reggie Penn, global head of technology alliances at Boomi. “A leader in the enterprise content management space, Laserfiche is a solid addition to our profile of partners that offer real solutions that help organizations solve their biggest challenges. The collaboration between Laserfiche and Boomi positions our mutual customers to meet the growing demand for integrations and keep up with the rapid pace of innovation.”
Learn more about the Laserfiche and Boomi partnership by visiting the Laserfiche website.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005010/en/
Contact information
Linda Domingo
Director, Public Relations, Laserfiche
Linda.domingo@laserfiche.com
562-988-1688 ext. 234
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom